Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 4/20 | 0.53 |
| ▸ | AXL | P30530 | 2/20 | 0.53 |
| ▸ | IDO1 | P14902 | 3/20 | 0.50 |
| ▸ | MET | P08581 | 1/20 | 0.50 |
| ▸ | METAP2 | P50579 | 2/20 | 0.49 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.46 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.41 |
| ▸ | TEC | P42680 | 1/20 | 0.41 |
| ▸ | TXK | P42681 | 1/20 | 0.41 |
| ▸ | BLK | P51451 | 1/20 | 0.41 |
| ▸ | BMX | P51813 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | ITK | Q08881 | 1/20 | 0.41 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30751781 | 1.00 | NOS1 (0.53) | NOS1AXLIDO1METMETAP2 | |
| SCHEMBL2011601 | 0.81 | NOS1 (0.53) | NOS1AXLIDO1METMETAP2 | |
| SCHEMBL4061625 | 0.81 | NOS1 (0.58) | NOS1AXLIDO1METMETAP2 | |
| SCHEMBL30135663 | 0.78 | IDO1 (0.51) | NOS1AXLIDO1METMETAP2 | |
| SCHEMBL2430327 | 0.76 | TRPA1 (0.42) | NOS1AXLIDO1METMETAP2 | |
| SCHEMBL4055516 | 0.75 | IDO1 (0.53) | NOS1AXLIDO1METMETAP2 | |
| SCHEMBL19475693 | 0.74 | METAP2 (0.38) | NOS1AXLIDO1METMETAP2 | |
| SCHEMBL5407599 | 0.74 | MET (0.44) | NOS1AXLIDO1METMETAP2 | |
| SCHEMBL13745163 | 0.74 | NOS1 (0.46) | NOS1AXLIDO1METMETAP2 | |
| SCHEMBL2861366 | 0.74 | TRPA1 (0.44) | NOS1AXLIDO1METMETAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110139862-B | Substituted bicyclic heterocyclic derivatives useful as ROMK channel inhibitors | 百时美施贵宝公司 | 2024-01-16 | — | — | CN | claimed |
| EP-3445762-B1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2023-09-13 | — | — | EP | claimed |
| EP-3445762-B1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2023-09-13 | — | — | EP | disclosed |
| EP-3445762-B1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2023-09-13 | — | — | EP | disclosed |
| CN-110885328-B | Sulfonamide compounds as sodium channel blockers and uses thereof | 成都康弘药业集团股份有限公司 | 2022-08-12 | — | — | CN | disclosed |
| EP-3535258-B1 | SUBSTITUTED BICYCLE HETEROCYCLIC DERIVATIVES USEFUL AS ROMK CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-11-24 | — | — | EP | disclosed |
| CN-109311874-B | Substituted bicyclic heterocyclic compounds | 百时美施贵宝公司 | 2021-07-30 | — | — | CN | disclosed |
| US-10991895-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2021-04-27 | — | — | US | disclosed |
| US-10851108-B2 | Substituted bicyclic heterocyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-12-01 | — | — | US | disclosed |
| US-10851108-B2 | Substituted bicyclic heterocyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-12-01 | — | — | US | disclosed |
| CN-106458996-B | Fused pyrimidines as inhibitors of the p97 complex | 克里弗生物科学公司 | 2020-11-03 | — | — | CN | disclosed |
| EP-1756054-B1 | 3-AMINO-1-ARYLPROPYL INDOLES AS MONOAMINE REUPTAKE INHIBITOR | HOFFMANN LA ROCHE (CH) | 2010-03-31 | — | — | EP | disclosed |
| EP-1756054-B1 | 3-AMINO-1-ARYLPROPYL INDOLES AS MONOAMINE REUPTAKE INHIBITOR | HOFFMANN LA ROCHE (CH) | 2010-03-31 | — | — | EP | disclosed |
| CN-101663297-A | Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (s1p) agonists | GLAXO GROUP LTD | 2010-03-03 | — | — | CN | disclosed |
| US-20080076924-A1 | Piperazines as P2X7 antagonists | ABBOTT LABORATORIES | 2008-03-27 | — | — | US | disclosed |
| EP-1807077-A2 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-18 | — | — | EP | disclosed |
| EP-1756054-A1 | 3-AMINO-1-ARYLPROPYL INDOLES AS MONOAMINE REUPTAKE INHIBITOR | F.HOFFMANN-LA ROCHE AG (CH) | 2007-02-28 | — | — | EP | disclosed |
| WO-2006047277-A2 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-05-04 | — | — | WO | disclosed |
| US-20060025467-A1 | 3-amino-1-arylpropyl indoles as monoamine reuptake inhibitors | ROCHE PALO ALTO LLC | 2006-02-02 | — | — | US | disclosed |
| WO-2005118539-A1 | 3-AMINO-1-ARYLPROPYL INDOLES AS MONOAMINE REUPTAKE INHIBITOR | F.HOFFMANN-LA ROCHE AG (CH) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10991895-B2 | Organic electroluminescent materials and devices | ICMT, GFPT1, PCMT1 | NOS1 1619/4885AXL 1706/4885IDO1 1945/4885 |
| US-20060025467-A1 | 3-amino-1-arylpropyl indoles as monoamine reuptake inhibitors | TPH1, HTR1A, HTR3A | NOS1 891/4885AXL 3407/4885IDO1 36/4885 |
| US-10851108-B2 | Substituted bicyclic heterocyclic compounds | NR0B1, GRK4, CRKL | NOS1 737/4885AXL 2923/4885IDO1 3948/4885 |
| US-20080076924-A1 | Piperazines as P2X7 antagonists | P2RX7, P2RX1, P2RX2 | NOS1 1803/4885AXL 1759/4885IDO1 865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.